Sugi Predict

Sugi Predict / Compounds / SCHEMBL22245252

SCHEMBL22245252

SCHEMBL22245252

C=CCn1ncc2nc(Cl)nc(Cl)c21

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ PDE4B Q07343 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ TUBB4A P04350 1/20 0.30
▸ TUBB P07437 1/20 0.30
▸ TUBA3C P0DPH7 1/20 0.30
▸ TUBA1B P68363 1/20 0.30
▸ TUBA4A P68366 1/20 0.30
▸ TUBB4B P68371 1/20 0.30
▸ TUBB3 Q13509 1/20 0.30
▸ TUBB2A Q13885 1/20 0.30
▸ TUBB8 Q3ZCM7 1/20 0.30
▸ TUBA3E Q6PEY2 1/20 0.30
▸ TUBA1A Q71U36 1/20 0.30
▸ TUBA1C Q9BQE3 1/20 0.30
▸ TUBB6 Q9BUF5 1/20 0.30
▸ TUBB2B Q9BVA1 1/20 0.30
▸ TUBB1 Q9H4B7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19661198 0.72 PDE4B (0.38) PDE4BPDE4D
SCHEMBL22119225 0.72 EGLN1 (0.36) RAB9ASMN1; SMN2
SCHEMBL31138676 0.70 TUBB4A (0.32) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1609689 0.69 TUBB4A (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL4101021 0.69 NPBWR1 (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL22118906 0.66 PDE4B (0.33) PDE4BPDE4D
SCHEMBL29601777 0.66 ADORA2B (0.39) PDE4BPDE4D
SCHEMBL31725530 0.66 SMN1; SMN2 (0.41) RAB9ASMN1; SMN2
SCHEMBL29689773 0.65 TUBB4A (0.34) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL20023761 0.65 TUBB4A (0.34) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof Acurx Pharmaceuticals, Inc. (US) 2026-01-27 — — US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-20220112195-A1 DNA Polymerase IIIC Inhibitors and Use Thereof ACURX PHARMACEUTICALS LLC (US) 2022-04-14 — — US disclosed
CN-113507929-A DNA polymerase IIIC inhibitor and application thereof 阿科利斯制药有限责任公司 2021-10-15 — — CN disclosed
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2021-05-11 — — US disclosed
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2021-05-11 — — US disclosed
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-11-17 — — US disclosed
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-11-17 — — US disclosed
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-07-28 — — US disclosed
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-07-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112195-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB RAB9A 4572/4885SMN1; SMN2 4322/4885PDE4B 1290/4885
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof POLR1A, POLR2H, POLN RAB9A 3497/4885SMN1; SMN2 3802/4885PDE4B 2612/4885
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB RAB9A 4564/4885SMN1; SMN2 4276/4885PDE4B 1221/4885
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB RAB9A 4572/4885SMN1; SMN2 4322/4885PDE4B 1290/4885
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB RAB9A 4564/4885SMN1; SMN2 4276/4885PDE4B 1221/4885
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB RAB9A 4564/4885SMN1; SMN2 4276/4885PDE4B 1221/4885
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB RAB9A 4572/4885SMN1; SMN2 4322/4885PDE4B 1290/4885
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB RAB9A 4564/4885SMN1; SMN2 4276/4885PDE4B 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.